TPE:6446

4 stories mentioning TPE:6446Updated just now

Every FINWIRES story that references TPE:6446, newest first.

PharmaEssentia's Besremi Wins Macau Import Approval; Shares Surge 9%

PharmaEssentia's (TPE:6446) said the Institute of Pharmaceutical Supervision and Administration of Macau approved adding a new indication to the prior authorization for the import of medicines for Besremi, according to a Sunday filing with the Taiwan Exchange.The medication is used to treat adult patients with essential thrombocythemia.Following the approval, the drug can now be exported to and marketed and sold in Macau for the newly approved indication.Shares of the biopharmaceutical company surged over 9% in Monday trading.

TPE:6446

Asia25d ago

PharmaEssentia Swings to Profit in May as Revenue Balloons 108%

PharmaEssentia (TPE:6446) reported May net profit attributable to shareholders of NT$993 million, compared with a loss a year earlier, according to a Wednesday Taiwan Exchange filing.Revenue for the month ballooned 108% year-on-year to NT$2.46 billion, while earnings were NT$2.66 per share.For the first quarter, audited net profit attributable to shareholders increased 70% from a year earlier to NT$2.15 billion. Meanwhile, revenue soared 57% annually to NT$5.12 billion.

TPE:6446

Asia46d ago

PharmaEssentia Rebuffs Media Report Speculating Profit, Revenue for 2026

PharmaEssentia (TPE:6446) refuted a Commercial Times report claiming that the company's full-year 2026 revenue could exceed NT$20 billion, and profits may surpass two times paid-in capital, potentially making it the most profitable biotech firm in the sector.The biotech company described the figures as speculative, stating that it did not provide any financial or business forecasts, according to a Thursday Taiwan Exchange filing.It added that investors should rely solely on official disclosures via the Market Observation Post System, according to its filing.

TPE:6446

Asia53d ago

PharmaEssentia Completes Enrollment for Phase III Primary Myelofibrosis Drug Study

PharmaEssentia (TPE:6446) completed the enrollment of 160 patients in a Phase III clinical trial testing its drug ropeginterferon alfa-2b (P1101) for early and low-risk primary myelofibrosis.The global study, called HOPE-PMF, is expected to be completed in 2027, according to a Wednesday Taiwan Exchange filing.The company said the drug is already approved for other blood disorders in several countries, but this new indication is still under development.

TPE:6446

Track with the FINWIRES app suite

FolioX

Track TPE:6446 in your portfolio

WheelAI

Analyze TPE:6446 options with the wheel strategy

StockInsider

See market sentiment on TPE:6446